Organogenesis Holdings 将来の成長

Future 基準チェック /36

Organogenesis Holdings利益と収益がそれぞれ年間123.3%と4.6%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に1.2% 122.5%なると予測されています。

主要情報

123.3%

収益成長率

122.5%

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	4.6%
将来の株主資本利益率	1.2%
アナリストカバレッジ	Low
最終更新日	15 Nov 2024

今後の成長に関する最新情報

Recent updates

Organogenesis: Lurking Disruption With Recovery To Follow

Oct 15

Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S

Sep 09

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Jun 10

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

May 21

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

May 01

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Apr 10

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Jan 04

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

May 31

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Jan 19

Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio

Oct 18

業績と収益の成長予測

NasdaqCM:ORGO - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	511	13	N/A	N/A	3
12/31/2025	470	2	N/A	N/A	4
12/31/2024	464	-9	N/A	N/A	4
9/30/2024	455	-7	4	14	N/A
6/30/2024	448	-17	9	22	N/A
3/31/2024	435	6	7	26	N/A
12/31/2023	433	5	7	31	N/A
9/30/2023	449	13	-4	28	N/A
6/30/2023	457	10	-19	17	N/A
3/31/2023	461	13	-16	18	N/A
12/31/2022	451	16	-9	25	N/A
9/30/2022	463	59	7	35	N/A
6/30/2022	460	71	23	57	N/A
3/31/2022	462	83	32	65	N/A
12/31/2021	467	94	31	62	N/A
9/30/2021	446	62	36	67	N/A
6/30/2021	433	69	28	48	N/A
3/31/2021	379	43	3	21	N/A
12/31/2020	338	17	-12	5	N/A
9/30/2020	306	-5	-40	-24	N/A
6/30/2020	270	-37	-50	-38	N/A
3/31/2020	266	-42	-51	-41	N/A
12/31/2019	261	-39	-40	-34	N/A
9/30/2019	250	-46	-48	-45	N/A
6/30/2019	236	-48	-65	-62	N/A
3/31/2019	215	-58	-68	-66	N/A
12/31/2018	193	-65	-62	-61	N/A
9/30/2018	183	-60	-48	-46	N/A
6/30/2018	184	-52	N/A	-25	N/A
3/31/2018	187	-32	N/A	-9	N/A
12/31/2017	199	-9	N/A	-3	N/A
12/31/2016	139	-17	N/A	-5	N/A
12/31/2015	99	-24	N/A	-10	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ORGOは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.6% ) よりも高い成長率であると考えられます。

収益対市場: ORGO今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: ORGO今後 3 年以内に収益を上げることが予想されます。

収益対市場: ORGOの収益 ( 4.6% ) US市場 ( 8.9% ) よりも低い成長が予測されています。

高い収益成長: ORGOの収益 ( 4.6% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ORGOの自己資本利益率は、3年後には低くなると予測されています ( 1.2 %)。

Organogenesis Holdings 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Consensus estimates of losses per share improve by 64%

Price target increased by 7.4% to US$4.70

Consensus EPS estimates fall by 492%

Price target decreased by 11% to US$4.17

Consensus EPS estimates fall by 267%

Consensus EPS estimates upgraded to US$0.01 loss

Recent updates

Consensus estimates of losses per share improve by 64%

Price target increased by 7.4% to US$4.70

Organogenesis Holdings Inc. announced that it expects to receive $130 million in funding from Avista Healthcare Partners III, L.P. and AHP III Orchestra Holdings, L.P

New minor risk - Share price stability

Organogenesis Holdings Inc. announced that it expects to receive $130 million in funding from Avista Healthcare Partners

Organogenesis Holdings Inc. Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Organogenesis Holdings Inc. to Report Q3, 2024 Results on Nov 12, 2024

Organogenesis: Lurking Disruption With Recovery To Follow

Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S

Consensus EPS estimates fall by 492%

Second quarter 2024 earnings released: US$0.13 loss per share (vs US$0.04 profit in 2Q 2023)

Organogenesis Holdings Inc. Shares Renu Program Update

Investor sentiment deteriorates as stock falls 18%

Organogenesis Holdings Inc. to Report Q2, 2024 Results on Aug 08, 2024

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Price target decreased by 11% to US$4.17

Consensus EPS estimates fall by 267%

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

Investor sentiment improves as stock rises 25%

Consensus EPS estimates upgraded to US$0.01 loss

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

First quarter 2024 earnings released: US$0.016 loss per share (vs US$0.023 loss in 1Q 2023)

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

Organogenesis Holdings Inc., Annual General Meeting, Jun 20, 2024

Investor sentiment deteriorates as stock falls 20%

Organogenesis Holdings Inc. to Report Q1, 2024 Results on May 09, 2024

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

Chief Operating Officer exercised options to buy US$432k worth of stock.

Consensus EPS estimates fall from profit to US$0.013 loss

New minor risk - Earnings quality

Full year 2023 earnings: EPS and revenues miss analyst expectations

Organogenesis Holdings Inc. Provides Earnings Guidance for the First Quarter and for the Year Ending December 31, 2024

Investor sentiment improves as stock rises 20%

Organogenesis Holdings Inc. to Report Q4, 2023 Results on Feb 29, 2024

Insider recently sold US$77k worth of stock

Investor sentiment improves as stock rises 17%

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Investor sentiment improves as stock rises 22%

Consensus forecasts updated

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorates as stock falls 15%

High number of new directors

Organogenesis Holdings Inc. to Report Q3, 2023 Results on Nov 09, 2023

Organogenesis Holdings Inc. Withdraws Earnings Guidance for the the 2023

Investor sentiment deteriorates as stock falls 20%

Investor sentiment improves as stock rises 16%

Organogenesis Holdings Inc. to Report Q2, 2023 Results on Aug 09, 2023

Organogenesis Holdings Inc. to Report Q2, 2023 Results on Aug 09, 2023

Investor sentiment deteriorates as stock falls 15%

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Investor sentiment improves as stock rises 23%

Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year 2023

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improves as stock rises 16%

Insider recently sold US$104k worth of stock

Investor sentiment deteriorates as stock falls 15%

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment deteriorates as stock falls 17%

Organogenesis Holdings Inc. to Report Q4, 2022 Results on Mar 01, 2023

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

High number of new directors

Third quarter 2022 earnings released: EPS: US$0.002 (vs US$0.098 in 3Q 2021)

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio

Organogenesis Holdings Inc. to Report Q3, 2022 Results on Nov 09, 2022